EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Body mass index at diagnosis, postdiagnosis change, and role of metabolic comorbidities in relation to survival in nonmetastatic renal cell carcinoma patients

Monica Sarker iD, Zhengyi Deng, Eric C Kauffman, Li Tang, Marilyn L Kwan iD, Marvin E Langston, Sumati Gupta, G Daniel Grass iD, Eric A Singer, Yousef Zakharia, Paul V Viscuse iD, Laura Graham und 10 weitere

Cancer · 01.11.2026 · 132 (21)

DOI: 10.1002/cncr.70653 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer, online erschienen am 23.10.2026. Verfasst von Monica Sarker und 21 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cancer Prevention and Control, Roswell Park Comprehensive Cancer Center, Buffalo, New York, USA. Hauptthemen laut MEDLINE: Carcinoma, Renal Cell, Body Mass Index, Kidney Neoplasms, Obesity. Die Arbeit nennt 71 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NCI NIH HHS, US Army Medical Research and Development Command.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Obesity is a recognized risk factor for renal cell carcinoma (RCC) incidence, but higher body mass index (BMI) measured at diagnosis has been paradoxically associated with improved survival. This study investigated whether postdiagnosis changes in BMI and metabolic comorbidities combined with BMI at diagnosis are associated with survival.

Methods

This study examined 1289 patients with nonmetastatic RCC (stage I–III) from the Oncology Research Information Exchange Network. BMI was assessed at diagnosis and at 2 and 3 years postdiagnosis. Multivariable Cox regression and restricted cubic spline models estimated hazard ratios (HRs) for overall survival (OS) and disease‐free survival (DFS).

Results

Modest weight gain (10% loss at 2 years: OS HR, 7.77; 95% CI, 3.00–20.16; DFS HR, 3.13; 95% CI, 1.68–5.82), independent of BMI at diagnosis, whereas substantial weight gain was associated with worse OS (>10% gain at 3 years: OS HR, 3.26; 95% CI, 1.14–9.32). Nonobese patients with diabetes had significantly worse DFS (HR, 1.83; 95% CI, 1.22–2.76), whereas the association between obesity and improved survival was mainly limited to patients without diabetes (HR, 0.75; 95% CI, 0.58–0.97).

Conclusions

Postdiagnosis weight trajectory and metabolic health are important prognostic factors for nonmetastatic RCC. Weight stability and absence of diabetes were associated with more favorable outcomes. Incorporating repeated BMI measurements and diabetes status may improve risk stratification during RCC survivorship.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Renal CellBody Mass IndexKidney NeoplasmsObesityHumansFemaleMaleMiddle AgedAgedComorbidityRisk FactorsWeight GainWeight LossDisease-Free SurvivalPrognosisAdult

Stichwörter der Autor:innen

body mass indexdiabetesobesity paradoxrenal cell carcinomaweight change

Autor:innen und Institutionen

  • Department of Cancer Prevention and Control, Roswell Park Comprehensive Cancer Center, Buffalo, New York, USA.
  • Department of Urology, Stanford University School of Medicine, Stanford, California, USA.
  • Department of Epidemiology, Stanford University, Palo Alto, California, USA.
  • Department of Urology, Roswell Park Comprehensive Cancer Center, Buffalo, New York, USA.
  • Division of Research, Kaiser Permanente Northern California, Pleasanton, California, USA.
  • Huntsman Cancer Institute, Salt Lake City, Utah, USA.

ORCID-Profile: Monica Sarker, Marilyn L Kwan, G Daniel Grass, Paul V Viscuse

Förderung

  • NCI NIH HHS
  • US Army Medical Research and Development Command

Zitieren

APA

Sarker, M., Deng, Z., Kauffman, E. C., Tang, L., Kwan, M. L., Langston, M. E., Gupta, S., Grass, G. D., Singer, E. A., Zakharia, Y., Viscuse, P. V., Graham, L., Ghodoussipour, S., Salhia, B., Kern, S. Q., Ayanambakkam, A., Myint, Z., King, J., Oderinde, S., …, & Batai, K. (2026). Body mass index at diagnosis, postdiagnosis change, and role of metabolic comorbidities in relation to survival in nonmetastatic renal cell carcinoma patients. Cancer, 132(21). https://doi.org/10.1002/cncr.70653

Vancouver

Sarker M, Deng Z, Kauffman EC, Tang L, Kwan ML, Langston ME, et al. Body mass index at diagnosis, postdiagnosis change, and role of metabolic comorbidities in relation to survival in nonmetastatic renal cell carcinoma patients. Cancer. 2026;132(21). doi:10.1002/cncr.70653

BibTeX
@article{Sarker2026,
  author = {Sarker, Monica and Deng, Zhengyi and Kauffman, Eric C and Tang, Li and Kwan, Marilyn L and Langston, Marvin E and Gupta, Sumati and Grass, G Daniel and Singer, Eric A and Zakharia, Yousef and Viscuse, Paul V and Graham, Laura and Ghodoussipour, Saum and Salhia, Bodour and Kern, Sean Q and Ayanambakkam, Adanma and Myint, Zin and King, Jennifer and Oderinde, Seyi and Churchman, Michelle L and Rounbehler, Robert J and Batai, Ken},
  title = {Body mass index at diagnosis, postdiagnosis change, and role of metabolic comorbidities in relation to survival in nonmetastatic renal cell carcinoma patients},
  journal = {Cancer},
  year = {2026},
  volume = {132},
  number = {21},
  doi = {10.1002/cncr.70653}
}
Kostenlos starten →